Market Place
Sourcing Support
Biologics gaining ground in HS, but more support needed: Spherix
11 Nov 2024 //
FIERCE PHARMA
Novartis`s Biologic Cosentyx (Secukinumab) Receives Approval in US
04 Oct 2024 //
FDA
Novartis` Cosentyx gets US nod for hidradenitis suppurativa
01 Nov 2023 //
GLOBENEWSWIRE
Novartis` Biologic Cosentyx (secukinumab) Receives Approval in the U.S.
31 Oct 2023 //
FDA
Novartis gets US nod for intravenous form of Cosentyx
07 Oct 2023 //
PR NEWSWIRE
Novartis`s Cosentyx (secukinumab) Receives Approval in Europe
13 Jun 2023 //
EMA
Novartis receives European approval for Cosentyx
01 Jun 2023 //
PRESS RELEASE
Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.
11 May 2023 //
FDA
Novartis targets new fields—and CAR-T—for immunology growth
11 May 2023 //
FIERCE PHARMA
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
27 Apr 2023 //
PRESS RELEASE
Patients with hidradenitis suppurativa experienced efficacy with Cosentyx
03 Feb 2023 //
GLOBENEWSWIRE
AbbVie sheds autoimmune disease drug in blow to partner Inventiva
31 Oct 2022 //
PHARMAPHORUM
Novartis ties HQ raid to Cosentyx patent fight against Lilly
26 Oct 2022 //
FIERCEPHARMA
Novartis Cosentyx shows improvements with hidradenitis suppurativa
09 Sep 2022 //
GLOBENEWSWIRE
EU approves Norvatis’ Cosentyx for childhood arthritis
30 Jun 2022 //
PHARMATIMES
Novartis Cosentyx nabs +ve CHMP opinion for expanded use in childhood arthritis
20 May 2022 //
GLOBENEWSWIRE
Novartis` Biologic Cosentyx (Secukinumab) Receives Approval in the U.S.
22 Dec 2021 //
FDA
FDA Approves Cosentyx in enthesitis-related arthritis, psoriatic arthritis
22 Dec 2021 //
PRNEWSWIRE
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
16 Nov 2021 //
FIERCEBIOTECH
Cosentyx displays a 72 percent reduced arthritis flare risk
10 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
Novartis’ Cosentyx cuts flare risk in juvenile idiopathic arthritis trial
09 Nov 2021 //
CLINICALTRIALSARENA
Novartis autoinjector effective for treating psoriasis
29 Sep 2021 //
PHARMAFILE
Key players in psoriasis offer strong support through branded digital channels
13 Sep 2021 //
BIOSPECTRUM ASIA
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
03 Sep 2021 //
PHARMATIMES
NICE approves secukinumab for young people with severe plaque psoriasis
03 Sep 2021 //
PHARMA FILE
Kevin Judice plays DiCE, pivoting from a $60M raise
27 Aug 2021 //
ENDPTS
China NMPA approves Novartis’ Cosentyx in pediatric patients
19 Aug 2021 //
PHARMABIZ
Novartis secures new approval in China for Cosentyx in pediatric psoriasis
17 Aug 2021 //
PRESS RELEASE
Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
17 Jun 2021 //
PHARMATIMES
Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric
02 Jun 2021 //
ENDPTS
Novartis Cosentyx receives FDA approval for treatment of children & adolescents
01 Jun 2021 //
PRESS RELEASE
Cosentyx gains EU approval for new label extension
02 Mar 2021 //
PHARMATIMES
Secukinumab in children with plaque psoriasis: Study unsuitable
04 Dec 2020 //
EUREKALERT
Novartis reports positive results from Cosentyx trial
30 Oct 2020 //
CLINICALTRIALSARENA
Novartis presents latest Phase III data reinforcing Cosentyx®
29 Oct 2020 //
NOVARTIS
Novartis puts spokesceleb Cyndi Lauper in host chair for life-with-psoriasis
28 Aug 2020 //
FIERCEPHARMA
AbbVie`s Skyrizi stands to gain as docs move away from older psoriasis meds
25 Aug 2020 //
FIERCEPHARMA
Novartis Cosentyx® receives EU approval for first-line systemic treatment
03 Aug 2020 //
PRESS RELEASE
Bimekizumab shows positive phase 3b results against Cosentyx
24 Jul 2020 //
HEALIO
UCB touts another psoriasis win, this time over Cosentyx, as they look to break
24 Jul 2020 //
ENDPTS
UCB`s investigational IL-17A and IL-17F inhibitor outclasses Novartis` Cosentyx
23 Jul 2020 //
PHARMAFILE
Lilly`s Mirikizumab Superior to Cosentyx® (secukinumab)
16 Jul 2020 //
PRNEWSWIRE
EMA committee recommends approval of Novartis Cosentyx
28 Jun 2020 //
PHARMABIZ
Cosmo receives positive EMA CHMP Opinion recommending approval
26 Jun 2020 //
PRESS RELEASE
Novartis`s Cosentyx (Secukinumab) Receives Supplemental Approval in US
23 Jun 2020 //
FDA
Lilly`s Taltz outpaces Novartis` Cosentyx with 4th FDA approval
01 Jun 2020 //
FIERCE PHARMA
Novartis wins expanded European OK for Cosentyx amid pursuit of $5 billion sales
29 Apr 2020 //
REUTERS
EMA committee recommends approval of Novartis’ Cosentyx to treat radiographic
30 Mar 2020 //
PHARMABIZ
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial
27 Mar 2020 //
PRESS RELEASE
Cosentyx, Entresto drive topline growth for Novartis in Q4
30 Jan 2020 //
PMLIVE
Is mainstream DTC the go-to marketing path for biologics now?
28 Jan 2020 //
FIERCE PHARMA
New Phase 3 Data Show SKYRIZI Superior to Cosentyx in Plaque Psoriasis
15 Jan 2020 //
PR NEWSWIRE
AbbVie`s new hope Skyrizi bests Novartis` Cosentyx at clearing patients` skin
15 Jan 2020 //
FIERCE PHARMA
Novartis, Cyndi Lauper shine a light on psoriasis challenges in the workplace
26 Nov 2019 //
FIERCE PHARMA
Cosentyx hits endpoints in axSpA trial
13 Nov 2019 //
PHARMA TIMES
Novartis Cosentyx shows encouraging results versus Humira
04 Nov 2019 //
PHARMABIZ
Cosentyx ‘narrowly’ misses superiority VS Humira
02 Nov 2019 //
PHARMATIMES
Novartis arthritis drug falls short in challenge to global bestseller
02 Nov 2019 //
REUTERS
Novo drops oral GLP-1 analog to focus on next-gen Rybelsus
01 Nov 2019 //
FIERCE BIOTECH
Cosentyx receives EU label update
24 Oct 2019 //
PHARMATIMES
